Navigation Links
SeqWright's Clinical Trial Support Contributes to the Approval of Two HPV Diagnostic Systems
Date:4/7/2009

HOUSTON, April 7 /PRNewswire/ -- SeqWright Inc., an international leader in the field of contract genomic services, announced today its involvement in Hologic's (formerly Third Wave Technologies) successful clinical trials of two Human Papillomavirus (HPV) in vitro diagnostic tests. SeqWright provided FDA submission quality DNA sequencing of multiple HPV strains and bioinformatics support to validate two Hologic HPV diagnostic tests; Cervista HPV High Risk (HR) and Cervista HPV 16/18, in preparation for FDA submission. Both tests were recently awarded FDA premarket approval. According to Hologic, their Cervista HPV HR clinical trial involved over 4,000 women spread across 89 sites throughout the United States and constituted one of the largest and most demographically diverse clinical trials ever conducted in the United States.

SeqWright was selected to perform the sequencing-based validations of Hologic's HPV Diagnostics assays after successfully completing several of Hologic's previous clinical trials, which all led to FDA approvals. SeqWright maintains advanced quality control with a Clinical Laboratory Improvement Amendment (CLIA) certification as well as maintaining compliance with Good Laboratory Practices (GLPs) as specified in the Code of Federal Regulations.

Sequencing for Hologic's clinical trials was performed under GLP guidelines (4X-bidirectional sequencing, stringent controls, full documentation) and all samples were continuously tracked and monitored. The bioinformatics provided by SeqWright were also vital to trial success and were used to implement Hologic's HPV genotyping analysis as well as to create a customized clinical trial decision tree algorithm. These services led to a streamlined, reliable and efficient testing regimen in support of Hologic's two recently approved HPV Diagnostics.

SeqWright CEO, Dr. Fei Lu, M.D. stated, "We wish to congratulate Hologic on the
'/>"/>

SOURCE SeqWright Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)... Depression, anxiety disorder, bipo...rder (ADHD), sleep disorder and migraine: These ar...ften in people who said they had been diagnosed wi...osis, according to a survey of approximately 173,0..." CNS-Related Comorbidities in Individuals with Se...
(Date:12/3/2009)... Allen Medical Systems, a...C ), today announced the launch of its new Allen A...usiness website www.AllenAmatech.com . ,, T...identity and includes an online version of the new...esign specifications for the products. "We hope to...
(Date:12/3/2009)... A genetic variation that...entially life-threatening blood disorder if expose... is one of several medical discoveries scientists ...SE: DGX ) will present during the 51st American ...osition, December 5-8, 2009, in New Orleans, LA. ...
Breaking Medicine Technology:Looking Ahead to AES 2009: New Insights on Comorbidities and Other Considerations for Epilepsy Treatment 2Looking Ahead to AES 2009: New Insights on Comorbidities and Other Considerations for Epilepsy Treatment 3Allen Medical Systems Announces the Launch of New Allen Amatech(TM) OEM Website 2Quest Diagnostics Reveals New Genetic Discoveries for Testing for Leukemia, Lymphoma and Blood Clotting at 51st ASH Meeting and Exposition 2Quest Diagnostics Reveals New Genetic Discoveries for Testing for Leukemia, Lymphoma and Blood Clotting at 51st ASH Meeting and Exposition 3Nfocus Neuromedical Announces US Clearance of Unique Guiding Catheter with Uni body Internal Skeleton 54719 1Nfocus Neuromedical Announces US Clearance of Unique Guiding Catheter with Uni body Internal Skeleton 54719 2Transcept Announces Plans to Reduce Expenses by Decreasing Staff Following Recent Completion of Purdue U S License and Collaboration Agreement 54716 1Transcept Announces Plans to Reduce Expenses by Decreasing Staff Following Recent Completion of Purdue U S License and Collaboration Agreement 54716 2Transcept Announces Plans to Reduce Expenses by Decreasing Staff Following Recent Completion of Purdue U S License and Collaboration Agreement 54716 3Transcept Announces Plans to Reduce Expenses by Decreasing Staff Following Recent Completion of Purdue U S License and Collaboration Agreement 54716 4Transcept Announces Plans to Reduce Expenses by Decreasing Staff Following Recent Completion of Purdue U S License and Collaboration Agreement 54716 5CBI Hosts 5th Annual Pharma Biotech Enterprise Governance Risk and Controls Congress 13603 1CBI Hosts 5th Annual Pharma Biotech Enterprise Governance Risk and Controls Congress 13603 2
(Date:12/4/2009)..., , PEMBROKE, Bermuda, Dec. 4 /PRNew... Holdings, Ltd (NYSE: AWH ) today announced that...ficer, and Jack Sennott, Executive Vice,President ...enting at the 2009,Goldman Sachs U.S. Financial Se...Conference Center in New York City on Tuesday, Dec...
(Date:12/4/2009)..., , ANAHEIM, Calif., Dec. 4 /PRNewswire/...scent Healthcare, was selected as a finalist for t...forming Crescent,s business with the power of clou...ased on their innovative usage of Salesforce CRM o... customer success to their sales, marketing, partn...
(Date:12/4/2009)..., Working with mice, scientists at Johns Hopkins...ave shown that a protein made by a gene called "Tw...ately distinguish stem cells that drive aggressive...r cells. , Building on recent work suggesting th...in breast tumors that drives breast cancer, scient...
(Date:12/4/2009)...Outcomes same whether procedure done immediately o... Dec. 4 (HealthDay News) -- Timing of surgical rep...juries may not affect patient outcome, a new study...esult from traumatic knee dislocations that can oc...s. The optimal time to perform surgery to repair t...
(Date:12/4/2009)...Research and surveillance urged for at-risk patien...ews) -- Some childhood cancers, particularly Ewing... the risk of late recurrence, U.S. researchers hav... 12,795 five-year survivors of the most common ped...Cancer Survivor Study. , The researchers found ...
Breaking Medicine News(10 mins):Health News:Allied World to Present at the 2009 Goldman Sachs U.S. Financial Services Conference 2Health News:Crescent CIO '09 Dreamforce Conference Speaker and Award Finalist 2Health News:Potential new 'twist' in breast cancer detection 2Health News:Potential new 'twist' in breast cancer detection 3Health News:Timing of Multiple-Ligament Knee Surgery May Not Matter 2
... screenwriters have a lower life expectancy than n...ainly improve your health and longevity - but it d..., Texas, reveal the health risks of winning an Aca...4 years than mere nominees. This is despite having...
...rong connection between celiac disease and diabete...eliac disease in people with type 1 diabetes is ab.... Doctors have uncovered a new finding for diabeti...tion to gluten. Both CD and diabetes are common ch...
...ciation for Continence, a new study shows early in...evalence of incontinence. Incontinence is loss of ...any conditions can cause incontinence,// including... ...
...t they may one day be able to reverse some cases o...indings from an animal study that show infertile m...on to produce offspring.// According to resea...f those are a result of problems with sperm produc...
...th Care System, obese adults who undergo 'stomach ...covered 'hunger hormone' than either normal-weight... Dr. David E. Cumming from the Puget Sound Health...oblems such as type 2 diabetes and other chronic d...
... play a role in reducing the number of childhood d...who tested three different methods of zinc adminis...zinc reduced the risk of prolonged diarrhea// defi...er or the child's caregiver. More than 3 mill...
Other Medicine News:Health News:Decrease of 'Hunger Hormone' after Obesity Surgery 2
...YDON is a long-pulsed Nd:YAG laser system with a w...deep-lying, superficial as well as red and blue ve...pilation in patients with darker skin types (1 to ...vement of skin texture. The handpieces special des...
...he UroVysion Bladder Cancer Kit (UroVysion Kit) is...7, 17, and loss of the 9p21 locus via fluorescence...rom persons with hematuria suspected of having bla...tended for use, in conjunction with and not in lie...
The BTA TRAK® Assay
ARION Long-Pulsed Alexandrite Laser System
Medicine Products: